Interventional Cardiology
STEMI management
ST-elevation MI treatment and primary PCI
Emerging pathwayAlso known as: ST elevation MI, primary PCI, STEMI protocol
818
Clinical questions
335
Evidence-backed
100
Claims analyzed
Interventional Cardiology
ST-elevation MI treatment and primary PCI
Synthesized from 335 evidence-backed clinical questions linked to this topic — 16 supporting the intervention, 25 against the intervention, 6 still contested.
Does ticagrelor vs clopidogrel improve outcomes in Acute Coronary Syndrome?
Low Certainty− Favors harmticagrelor vs clopidogrel · Cardiac Output
62 studies (729,408 patients) provide low-certainty evidence against benefit of ticagrelor for Cardiac Output in Acute Coronary Syndrome.
Does aspirin vs placebo improve outcomes in ST segment elevation myocardial infarction?
Low Certainty− Favors harmaspirin vs placebo
10 studies (212,459 patients) provide low-certainty evidence against benefit of aspirin for the outcome in ST segment elevation myocardial infarction.
Does ticagrelor vs clopidogrel improve outcomes in ST segment elevation myocardial infarction?
Low Certainty+ Favors benefitticagrelor vs clopidogrel · Myocardial Infarction Hospitalization
17 studies (206,473 patients) provide low-certainty evidence for benefit of ticagrelor for Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction.
Does women vs placebo improve outcomes in ST segment elevation myocardial infarction?
Low Certainty− Favors harmwomen vs placebo
3 studies (180,455 patients) provide low-certainty evidence against benefit of women for the outcome in ST segment elevation myocardial infarction.
Does prasugrel vs ticagrelor improve outcomes in ST segment elevation myocardial infarction?
Low Certainty+ Favors benefitprasugrel vs ticagrelor
3 studies (170,048 patients) provide low-certainty evidence for benefit of prasugrel for the outcome in ST segment elevation myocardial infarction.
Does beta-blockers vs placebo improve outcomes in ST segment elevation myocardial infarction?
Low Certainty+ Favors benefitbeta-blockers vs placebo
10 studies (165,196 patients) provide low-certainty evidence for benefit of beta-blockers for the outcome in ST segment elevation myocardial infarction.
Does anakinra vs placebo improve outcomes in ST segment elevation myocardial infarction?
Insufficient~ Mixed resultsanakinra vs placebo · Myocardial Infarction Hospitalization
6 studies (586 patients) provide insufficient evidence with mixed findings regarding anakinra for Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction.
Does eptifibatide vs placebo improve outcomes in ST segment elevation myocardial infarction?
Insufficient~ Mixed resultseptifibatide vs placebo
6 studies (997 patients) provide insufficient evidence with mixed findings regarding eptifibatide for the outcome in ST segment elevation myocardial infarction.
Emerging evidence with 100 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does fibrinolytic therapy vs placebo improve outcomes in ST segment elevation myocardial infarction?
Low Certainty+ Favors benefitfibrinolytic therapy vs placebo · Myocardial Infarction Hospitalization
Does ticagrelor vs clopidogrel improve Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction?
Low Certainty+ Favors benefitticagrelor vs clopidogrel · Myocardial Infarction Hospitalization
Sessions from public journal clubs on Synapse. RSVP to join the live discussion.
Predictors of major adverse cardiac and cerebrovascular events after percutaneous coronary intervention in older adults: a systematic review and meta-analysis
BMC Geriatrics — Jalali A — Apr 2024
Neutrophil extracellular trap components and myocardial recovery in post-ischemic acute heart failure
PLoS ONE — Langseth M — Oct 2020
Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a<i>Leaders Free ACS</i>sub-study
European Heart Journal — Naber C — May 2016
The combination assessment of lipid pool and thrombus by optical coherence tomography can predict the filter no-reflow in primary PCI for ST elevated myocardial infarction
Medicine — Negishi Y — Dec 2017
Neprilysin levels at the acute phase of ST‐elevation myocardial infarction
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
STEMI management (also known as ST elevation MI, primary PCI, STEMI protocol). ST-elevation MI treatment and primary PCI
Synapse tracks 6 specific clinical questions in STEMI management, each synthesized independently from its own trial evidence. They include: "Does fibrinolytic therapy vs placebo improve outcomes in ST segment elevation myocardial infarction?"; "Does ticagrelor vs clopidogrel improve Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction?"; "Does metoprolol vs placebo improve Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction?"; "Does metoprolol vs placebo improve outcomes in ST segment elevation myocardial infarction?"; "Does anakinra vs placebo improve Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction?".
As of 2026-08-15, the scientific consensus on STEMI management is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/stemi-management.
Deterministic synthesis from Synapse's enriched corpus — 144 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every STEMI management paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search STEMI management papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
Clinical Cardiology — Bernelin H — Oct 2018